Astex Pharmaceuticals, Inc.
4140 Dublin Boulevard
About Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals is a leader in innovative drug discovery, development and commercialization, committed to the fight against cancer and other life-threatening diseases.
• Fiscal strength with significant cash, ongoing revenues and potential milestone payments
• Productive partnerships with top-tier pharmaceutical companies
• Rich product portfolio with multiple drugs in clinical development
• Visionary leadership backed by a world-class management team
We are a leader in innovative small-molecule therapeutics with particular expertise in fragment-based drug discovery, the most important advance in discovery chemistry in the last 20 years. Our primary areas of focus are oncology and hematology.
We are a publicly traded pharmaceutical company with strong cash reserves and royalty revenues from the sales of our product DACOGEN®. In addition, our partnerships could deliver significant product milestones and future royalties.
282 articles with Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals Presents Final Results Of Phase 2 Study Of SGI-110 In Treatment Naïve Elderly Acute Myeloid Leukemia At The European Hematology Association Meeting
Astex Pharmaceuticals to Present at American Association for Cancer Research-National Cancer Institute-EORTC
Astex Pharmaceuticals Announces Oral Presentation of SGI-110 AML Data at the European Cancer Congress
Japan's Otsuka Pharmaceutical Co., Ltd. Shells Out $886 Million for U.S. Cancer Firm Astex Pharmaceuticals
Astex Pharmaceuticals Sees Positive Results From SGI-110 AML Phase 2 Study; Stock Rockets +24.45% at Market Close (August 28, 2013)
Astex Pharmaceuticals Announces First Data Showing Early Combination Treatment of HSP90 Inhibitor AT13387 With Targeted Agents Delays Emergence of Resistance in Preclinical Models
Astex Pharmaceuticals Announces IND Candidate: ASTX727 a Potential Best-in-Class Oral Hypomethylator
Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Data at the Upcoming European Cancer Congress (ECCO-ESMO-ESTRO)